CytomX Therapeutics to Report Q1 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update Next Week

May 1, 2024

DENVER, Colo., May 01, 2024 (247marketnews.com)- CytomX Therapeutics, Inc. (Nasdaq:CTMX) will report its first quarter 2024 results and provide an update on its initial CX-904 (masked EGFRxCD3 Probody® T-cell engager) preliminary Phase 1a trial update on Wednesday, May 8, 2024, after the U.S. markets close, and host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (CTMX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.